Regions Financial Corporation
—- Market cap
- $25.92B
- Debt
- +$4.88B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 84% equity / 16% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: RF stock price at premium vs NVAX $30.43 current versus $9.13 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVAX's multiple
Implied fair value · at RF's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RF FY 2025 (ended Dec 31, 2025) · NVAX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 84% equity / 16% debt
Capital structure 83% equity / 17% debt · EV / Revenue 1.16x · EV / EBITDA 2.86x
RF carries the larger enterprise value at $30.81B against $1.31B; NVAX trades on the lower EV / Revenue multiple (1.16x vs 4.36x); NVAX on the lower EV / EBITDA (2.86x vs 6.30x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Regions Financial Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
NOVAVAX INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.26x
-2.76x
Net debt / EBITDA
Leverage against operating earnings
—
-0.84x
Cash and equivalents
Liquid reserves on the balance sheet
—
$735.08M
Total debt
Interest-bearing obligations outstanding
$4.88B
$353.17M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
RF vs JPM
Bank of America Corporation
RF vs BAC
Wells Fargo & Company
RF vs WFC
Citigroup Inc.
RF vs C
The Goldman Sachs Group, Inc.
RF vs GS
Morgan Stanley
RF vs MS
Moderna, Inc.
RF vs MRNA
BioNTech SE
RF vs BNTX
Emergent BioSolutions Inc.
RF vs EBS
ASTRAZENECA PLC
RF vs AZN
GSK plc
RF vs GSK
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.